481 related articles for article (PubMed ID: 22578536)
21. Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity.
Yao C; Johnson WM; Gao Y; Wang W; Zhang J; Deak M; Alessi DR; Zhu X; Mieyal JJ; Roder H; Wilson-Delfosse AL; Chen SG
Hum Mol Genet; 2013 Jan; 22(2):328-44. PubMed ID: 23065705
[TBL] [Abstract][Full Text] [Related]
22. Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein.
Yun H; Heo HY; Kim HH; DooKim N; Seol W
Bioorg Med Chem Lett; 2011 May; 21(10):2953-7. PubMed ID: 21474311
[TBL] [Abstract][Full Text] [Related]
23. Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.
Ray S; Liu M
Future Med Chem; 2012 Sep; 4(13):1701-13. PubMed ID: 22924508
[TBL] [Abstract][Full Text] [Related]
24. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake.
Zhou H; Huang C; Tong J; Hong WC; Liu YJ; Xia XG
Int J Biol Sci; 2011; 7(6):753-61. PubMed ID: 21698001
[TBL] [Abstract][Full Text] [Related]
25. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
[TBL] [Abstract][Full Text] [Related]
26. Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats.
Lee JW; Tapias V; Di Maio R; Greenamyre JT; Cannon JR
Neurobiol Aging; 2015 Jan; 36(1):505-18. PubMed ID: 25174649
[TBL] [Abstract][Full Text] [Related]
27. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.
Li X; Patel JC; Wang J; Avshalumov MV; Nicholson C; Buxbaum JD; Elder GA; Rice ME; Yue Z
J Neurosci; 2010 Feb; 30(5):1788-97. PubMed ID: 20130188
[TBL] [Abstract][Full Text] [Related]
28. Mouse models for LRRK2 Parkinson's disease.
Xu Q; Shenoy S; Li C
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S186-9. PubMed ID: 22166430
[TBL] [Abstract][Full Text] [Related]
29. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.
Gandhi PN; Chen SG; Wilson-Delfosse AL
J Neurosci Res; 2009 May; 87(6):1283-95. PubMed ID: 19025767
[TBL] [Abstract][Full Text] [Related]
30. A new approach to Parkinson's disease: inhibition of leucine-rich repeat kinase-2.
Doggrell SA
Expert Opin Investig Drugs; 2011 Apr; 20(4):587-90. PubMed ID: 21314482
[TBL] [Abstract][Full Text] [Related]
31. Dietary Amino Acids Impact LRRK2-Induced Neurodegeneration in Parkinson's Disease Models.
Chittoor-Vinod VG; Villalobos-Cantor S; Roshak H; Shea K; Abalde-Atristain L; Martin I
J Neurosci; 2020 Aug; 40(32):6234-6249. PubMed ID: 32605938
[TBL] [Abstract][Full Text] [Related]
32. A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity.
Dusonchet J; Li H; Guillily M; Liu M; Stafa K; Derada Troletti C; Boon JY; Saha S; Glauser L; Mamais A; Citro A; Youmans KL; Liu L; Schneider BL; Aebischer P; Yue Z; Bandopadhyay R; Glicksman MA; Moore DJ; Collins JJ; Wolozin B
Hum Mol Genet; 2014 Sep; 23(18):4887-905. PubMed ID: 24794857
[TBL] [Abstract][Full Text] [Related]
33. Targeting leucine-rich repeat kinase 2 in Parkinson's disease.
Chan SL; Angeles DC; Tan EK
Expert Opin Ther Targets; 2013 Dec; 17(12):1471-82. PubMed ID: 24206363
[TBL] [Abstract][Full Text] [Related]
34. New biochemical approaches towards understanding the Parkinson's disease-associated kinase, LRRK2.
Liou GY; Gallo KA
Biochem J; 2009 Oct; 424(1):e1-3. PubMed ID: 19839940
[TBL] [Abstract][Full Text] [Related]
35. Models of LRRK2-Associated Parkinson's Disease.
Xiong Y; Dawson TM; Dawson VL
Adv Neurobiol; 2017; 14():163-191. PubMed ID: 28353284
[TBL] [Abstract][Full Text] [Related]
36. Inhibitors of leucine-rich repeat kinase 2 (LRRK2): progress and promise for the treatment of Parkinson's disease.
Gilligan PJ
Curr Top Med Chem; 2015; 15(10):927-38. PubMed ID: 25832719
[TBL] [Abstract][Full Text] [Related]
37. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.
Lee BD; Shin JH; VanKampen J; Petrucelli L; West AB; Ko HS; Lee YI; Maguire-Zeiss KA; Bowers WJ; Federoff HJ; Dawson VL; Dawson TM
Nat Med; 2010 Sep; 16(9):998-1000. PubMed ID: 20729864
[TBL] [Abstract][Full Text] [Related]
38. Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration.
Tsika E; Kannan M; Foo CS; Dikeman D; Glauser L; Gellhaar S; Galter D; Knott GW; Dawson TM; Dawson VL; Moore DJ
Neurobiol Dis; 2014 Nov; 71():345-58. PubMed ID: 25174890
[TBL] [Abstract][Full Text] [Related]
39. Genetic mouse models for understanding LRRK2 biology, pathology and pre-clinical application.
Yue Z
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1(0 1):S180-2. PubMed ID: 22166428
[TBL] [Abstract][Full Text] [Related]
40. The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities.
Maekawa T; Mori S; Sasaki Y; Miyajima T; Azuma S; Ohta E; Obata F
Mol Neurodegener; 2012 Apr; 7():15. PubMed ID: 22534020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
